DE69302276D1 - Diagnostische Methode - Google Patents

Diagnostische Methode

Info

Publication number
DE69302276D1
DE69302276D1 DE69302276T DE69302276T DE69302276D1 DE 69302276 D1 DE69302276 D1 DE 69302276D1 DE 69302276 T DE69302276 T DE 69302276T DE 69302276 T DE69302276 T DE 69302276T DE 69302276 D1 DE69302276 D1 DE 69302276D1
Authority
DE
Germany
Prior art keywords
pct
sec
diagnostic method
date
date apr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69302276T
Other languages
English (en)
Other versions
DE69302276T2 (de
Inventor
David Tarin
Yasuhiro Matsumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27266293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69302276(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929215498A external-priority patent/GB9215498D0/en
Priority claimed from GB929224386A external-priority patent/GB9224386D0/en
Priority claimed from GB929226165A external-priority patent/GB9226165D0/en
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Application granted granted Critical
Publication of DE69302276D1 publication Critical patent/DE69302276D1/de
Publication of DE69302276T2 publication Critical patent/DE69302276T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
DE69302276T 1992-07-21 1993-07-20 Diagnostische Methode Revoked DE69302276T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929215498A GB9215498D0 (en) 1992-07-21 1992-07-21 Diagnostic method
GB929224386A GB9224386D0 (en) 1992-11-20 1992-11-20 Nucleic acid sequence
GB929226165A GB9226165D0 (en) 1992-12-16 1992-12-16 Nucleic acid sequence
PCT/GB1993/001520 WO1994002633A1 (en) 1992-07-21 1993-07-20 Diagnostic method

Publications (2)

Publication Number Publication Date
DE69302276D1 true DE69302276D1 (de) 1996-05-23
DE69302276T2 DE69302276T2 (de) 1996-09-19

Family

ID=27266293

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69302276T Revoked DE69302276T2 (de) 1992-07-21 1993-07-20 Diagnostische Methode

Country Status (7)

Country Link
US (1) US5830646A (de)
EP (1) EP0651822B1 (de)
JP (1) JP2800850B2 (de)
AT (1) ATE136940T1 (de)
CA (1) CA2139410A1 (de)
DE (1) DE69302276T2 (de)
WO (1) WO1994002633A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705436A1 (de) * 1993-06-22 1996-04-10 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur diagnose und analyse von mammakarzinomen
GB9317139D0 (en) * 1993-08-18 1993-10-06 Miniser For Agriculture Fisher Method and test kits for detection of bacteriophage
DE4431297A1 (de) * 1994-09-02 1996-03-07 Boehringer Ingelheim Int Monoklonaler Antikörper gegen CD44v6
CA2195404A1 (en) * 1994-07-21 1996-02-08 David Tarin Diagnostic method and probe
DE19545472A1 (de) * 1995-12-06 1997-06-12 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19653607A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
WO1999004036A1 (en) * 1997-07-14 1999-01-28 Isis Innovation Limited Cd44 based cancer detection
US20030170637A1 (en) * 2002-03-06 2003-09-11 Pirrung Michael C. Method of analyzing mRNA splice variants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4014510A1 (de) * 1990-05-07 1991-11-14 Kernforschungsz Karlsruhe Variante cd44-oberflaechenproteine, diese kodierende c-dna-sequenzen, antikoerper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie
IE912466A1 (en) * 1990-07-13 1992-01-15 Gen Hospital Corp Rapid immunoselection cloning method

Also Published As

Publication number Publication date
JP2800850B2 (ja) 1998-09-21
WO1994002633A1 (en) 1994-02-03
CA2139410A1 (en) 1994-02-03
ATE136940T1 (de) 1996-05-15
JPH08500731A (ja) 1996-01-30
EP0651822B1 (de) 1996-04-17
DE69302276T2 (de) 1996-09-19
EP0651822A1 (de) 1995-05-10
US5830646A (en) 1998-11-03

Similar Documents

Publication Publication Date Title
EP0554383A4 (de)
DE69531457D1 (en) Sulfonamide
GR3031488T3 (en) Laminin chains: diagnostic and therapeutic use
ATE311150T1 (de) Medizinisches instrument zur behandlung von biologischem gewebe sowie verfahren zum übertragen von druckwellen
ATE321570T1 (de) Verfahren zur behandlung von hämostatischen störungen durch lösliches p-selectin
AU2738195A (en) Tumor diagnosis and prognosis
ATE223051T1 (de) Verfahren zur diagnose gutartiger prostataerkrankungen
Kennett et al. Investigations into the cellular contribution to host tissue proteases and inhibitors in gingival crevicular fluid
DE69302276D1 (de) Diagnostische Methode
DE69624369D1 (de) Schutzhülle für eine sonde
AU7635396A (en) Treatment and diagnosis of infections due to helicobacter pylori
FI954499A (fi) Menetelmä ja analyysi
EP0535059B1 (de) Dna-sequenz für eine serin-protease und damit zusammenhängende gegenstände
MACKIE et al. A case of pagetoid reticulosis bearing the T cytotoxic suppressor surface marker on the lymphoid infiltrate: further evidence that pagetoid reticulosis is not a variant of mycosis fungoides
HK1002531A1 (en) New tumor diagnosing or therapeutical probe
DE69226775T2 (de) Dns-sequenzen von hpv42 papillomavirus :verwendungsmöglichkeit für diagnose
AU5027190A (en) Process for the determination, by means of free radicals, of the anti-oxidant properties of a living organism or a potentially agressive agent
Sharpe Gender role and psychological well-being in adult men.
ATE222762T1 (de) 4-hydroxycoumarin-3-carboxamide für die behandlung von nicht-insulin-abhängigen diabetes mellitus
ATE240352T1 (de) Komplexverbindungen zur diagnose von gefässerkrankungen
AU8144894A (en) Biphenyl iodinated derivatives and their diagnostic use
Owen Improved in vitro determination of the viability of Taenia saginata embryos
ATE140037T1 (de) Verfahren zur diagnose von nicht-insulin- abhängigem diabetes mellitus
ATE420210T1 (de) Diagnose des brustkrebsrisikos
Colorimeter i" l|"'l'iiite'" l'SS r imPlied> on the lmH of

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation